Join Our Triple O Research Newsletter And Stay Informed.
Maker of Hepatitis C Drug Formulates Deal with Generics for Poor Countries
Gilead Sciences, the maker of sofosbuvir, announced last Monday they had agreements with seven Indian generic drug makers to sell lower-cost versions of the $1.000 per day pill ,sofosbuvir (Sovaldi). In the United States, Sovaldi costs on average, $1,000 per pill or $84,000 for a typical 12-week course of treatment. It is likely to be sold in India for less than $1,800 for a 24 week course of treatment. The seven Indian generic drug makers will pay royalties to Gilead to manufacture the drug for 91 developing countries. More than half of the world’s population living with Hepatitis C live in these 91 countries.
If you are interested in learning more about hepatitis C or Sovaldi, please ask your healthcare provider today.
Hepatitis C is curable! Inquire today!